Table 3 Characteristics of patients across both ASD clinical trials
From: Development and evaluation of the Acromegaly Symptom Diary
Patient characteristics | ACROBAT Evolve (N = 13) | ACROBAT Edge (N = 47) |
|---|---|---|
Sex, n (%) | ||
Female | 6 (46.2) | 27 (57.4) |
Male | 7 (53.8) | 20 (42.6) |
Age, years | ||
Mean ± SD, median, n | 53.5 ± 13.76, 50.0, 13 | 52.0 ± 11.08, 51.0, 47 |
Min, Max | 29.0, 75.0 | 31.0, 71.0 |
Country, n (%) | ||
North America | 2 (15.4) | 8 (17.0) |
Europe | 7 (53.8) | 24 (51.1) |
Rest of world | 4 (30.8) | 15 (31.9) |
Acromegaly disease characteristics | ||
Duration since diagnosis, months | ||
Mean ± SD, median, n | 144.7 ± 89.39, 145.3, 13 | 113.3 ± 69.16, 112.5, 47 |
Min, Max | 17.2, 253.1 | 23.2, 365.1 |
Tumor size prior to pituitary surgery, mm | ||
Mean ± SD, median, n | 15.8 ± 6.82, 15.0, 9 | 18.6 ± 9.6, 17.0, 42 |
Min, Max | 6.0, 26.0 | 1.0, 43.0 |
Prior pituitary surgery (Yes), n (%) | 13 (100.0) | 37 (78.7) |
IGF-I postoperative (× nmol/L) | ||
Mean ± SD, median, n | 65.7 ± 27.13, 58.6, 13 | 71.4 ± 28.0, 60.8, 37 |
Min, Max | 34.4, 117.6 | 33.0, 139.6 |
GH (ng/mL) | ||
Mean ± SD, median, n | 0.9 ± 0.88, 0.6, 13 | 1.9 ± 3.7, 0.9, 47 |
Min, Max | 0.1, 3.4 | 0.1, 23.9 |